Keytruda’s success cements Merck’s stance in healthcare industry

Date: 2018-06-04   Author: Pankaj Singh  Category: #industry

Keytruda’s success cements Merck’s stance in healthcare industry

Keytruda, the immunotherapy to treat lung cancer being developed by Merck and Co., apparently showed improved survival when used as a stand-alone treatment for newly diagnosed lung cancer. A source at Merck stated that these results presented at the American Society for Clinical Oncology in Chicago established Keytruda as a benchmark treatment in healthcare industry against which other immunotherapies should be measured.

According to a report on the results, one trial was conducted with advanced non-small cell lung cancer studying 1,274 patients who before trial, were tested positive for the Keytruda targeted protein PDL1, to see if they can be treated without chemotherapy. Overall, patients treated with Keytruda were found to live for a median of 16.7 months in comparison with 12.1 months for patients on chemotherapy.

Keytruda patients with PDL1 above 50% apparently lived for a median of 20 months whereas chemo lived for 12.2 months. Severe side-effects of Keytruda occurred only in 18% patients, while 41% of chemotherapy patients exhibited side-effects – quite an extreme difference, claim healthcare industry experts.

Through an alternative trial, Merck confirmed that Keytruda trial patients lived for a median of 6.4 months before their condition deteriorated, compared with 4.8 months of chemotherapy alone.

Experts commented that the oncology industry is now moving towards a future where chemotherapy is not the only option, derived from the fact that immunotherapy has proved to be less toxic than chemotherapy.

With “newly diagnosed lung cancer” being considered the most lucrative opportunity in the field of oncology, Merck’s Keytruda is competing with treatments and drugs from Roche, Bristol-Myers Squibb and other players in the healthcare industry. These companies already have numerous approvals for a variety of cancer treatments but do not intend to lack behind on this prospect, developing drugs to boost the immune system for attacking tumors.



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Marina Bay Sands to kickstart $4.5B expansion project in April 2024

Author: Pankaj Singh

Well-known integrated resort operator, MBS (Marina Bay Sands) has reportedly been granted another year to begin implementing the U$4.5 billion development project with the reprieve given by the STB (Singapore Tourism B...


Mammography Systems Market by Manufacturers, Regions, Type and Application, Forecast to 2027

Author: Rahul Varpe

The global ‘Mammography Systems Market’ study delivers an overall evaluation for stakeholders looking to expand their reach spanning various geographies, contenders, solution providers, new entrants in the industry, as well as financia...


Animal Genetics Market | Global Industry Analysis, Segments, Drivers and Forecast to 2027

Author: Rahul Varpe

The global ‘Animal Genetics Market’ study delivers an overall evaluation for stakeholders looking to expand their reach spanning various geographies, contenders, solution providers, new entrants in the industry, as well as financial sp...